Taiwan · Delayed Price · Currency is TWD Welgene Biotech Statistics
Total Valuation
Welgene Biotech has a market cap or net worth of TWD 379.86 million. The enterprise value is 464.22 million.
| Market Cap | 379.86M |
| Enterprise Value | 464.22M |
Important Dates
The next estimated earnings date is Tuesday, November 10, 2026.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Welgene Biotech has 23.30 million shares outstanding.
| Current Share Class | 23.30M |
| Shares Outstanding | 23.30M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 10.49% |
| Owned by Institutions (%) | n/a |
| Float | 5.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.95 |
| PB Ratio | 1.37 |
| P/TBV Ratio | 1.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 13.06 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.16 |
| EV / EBITDA | 16.32 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.91, with a Debt / Equity ratio of 1.01.
| Current Ratio | 1.91 |
| Quick Ratio | 1.51 |
| Debt / Equity | 1.01 |
| Debt / EBITDA | 9.89 |
| Debt / FCF | -2.75 |
| Interest Coverage | -0.53 |
Financial Efficiency
Return on equity (ROE) is -0.49% and return on invested capital (ROIC) is -0.76%.
| Return on Equity (ROE) | -0.49% |
| Return on Assets (ROA) | -0.26% |
| Return on Invested Capital (ROIC) | -0.76% |
| Return on Capital Employed (ROCE) | -0.50% |
| Weighted Average Cost of Capital (WACC) | 3.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.67 |
| Inventory Turnover | 4.69 |
Taxes
| Income Tax | -107,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.90% in the last 52 weeks. The beta is 0.20, so Welgene Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -19.90% |
| 50-Day Moving Average | 17.33 |
| 200-Day Moving Average | 18.19 |
| Relative Strength Index (RSI) | 41.97 |
| Average Volume (20 Days) | 6,112 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Welgene Biotech had revenue of TWD 398.92 million and -1.64 million in losses. Loss per share was -0.07.
| Revenue | 398.92M |
| Gross Profit | 166.87M |
| Operating Income | -2.49M |
| Pretax Income | -1.49M |
| Net Income | -1.64M |
| EBITDA | 14.31M |
| EBIT | -2.49M |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 201.29 million in cash and 281.15 million in debt, with a net cash position of -79.87 million or -3.43 per share.
| Cash & Cash Equivalents | 201.29M |
| Total Debt | 281.15M |
| Net Cash | -79.87M |
| Net Cash Per Share | -3.43 |
| Equity (Book Value) | 277.63M |
| Book Value Per Share | 11.72 |
| Working Capital | 146.39M |
Cash Flow
In the last 12 months, operating cash flow was 29.09 million and capital expenditures -131.51 million, giving a free cash flow of -102.42 million.
| Operating Cash Flow | 29.09M |
| Capital Expenditures | -131.51M |
| Depreciation & Amortization | 16.80M |
| Net Borrowing | 85.46M |
| Free Cash Flow | -102.42M |
| FCF Per Share | -4.39 |
Margins
Gross margin is 41.83%, with operating and profit margins of -0.62% and -0.41%.
| Gross Margin | 41.83% |
| Operating Margin | -0.62% |
| Pretax Margin | -0.37% |
| Profit Margin | -0.41% |
| EBITDA Margin | 3.59% |
| EBIT Margin | -0.62% |
| FCF Margin | n/a |
Dividends & Yields
Welgene Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -0.43% |
| FCF Yield | -26.96% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 17, 2018. It was a forward split with a ratio of 1.08.
| Last Split Date | Aug 17, 2018 |
| Split Type | Forward |
| Split Ratio | 1.08 |
Scores
Welgene Biotech has an Altman Z-Score of 1.59 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.59 |
| Piotroski F-Score | 3 |